Enjoy complimentary customisation on priority with our Enterprise License!
The anti-inflammatory therapeutics market size is estimated to grow at a CAGR of 6.7% between 2022 and 2027. The anti-inflammatory therapeutics market size is forecast to increase by USD 39.32 billion. The growth of the market depends on several factors, including the increase in off-label use, the unmet need for safer biologics for RA, and the availability of improved diagnostic modalities.
This market report extensively covers market segmentation by application (RA, psoriasis, and MS), drug class (anti-inflammatory biologicals, corticosteroids, and NSAIDs), and geography (North America, Europe, Asia, and Rest of World). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, View Report Sample
Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The unmet need for safer biologics for RA is notably driving the anti-inflammatory drugs market growth. The use of biologics for the treatment of RA raises safety concerns among rheumatologists. Biologics are immunosuppressive in nature and target parts of the immune system that drive inflammation. Abatacept acts by blocking the communication between inflammatory T-cells; anakinra hampers the protein interleukin-1, which is responsible for inflammation; rituximab destroys white blood cells that cause inflammation; and tocilizumab targets interleukin-6, an immune system protein that causes inflammation. Biologics can cause many side effects because of their immune-modifying actions.
Although the safety of biologics is established in clinical trials, the safety data is limited to a small number of patients enrolled in trials. In addition, the clinical trials were of short duration. There is limited data available on safety issues that might arise during the long-term use of biologics. The use of TNF-alpha inhibitors has been associated with tuberculosis, and Salmonella infections, such as typhoid and listeria infections. Risks of malignancies were also high in patients undergoing TNF-alpha inhibitor treatment. Hence, the abovementioned factors are expected to drive the growth of the global anti-inflammatory drugs market during the forecast period.
The use of gene therapy for RA treatment is a major trend in the focused market. Chemical and biological molecules that are used to treat RA have certain limitations. Chemical or synthetic drugs can target normal physiological processes of the body and may have non-specific effects that may be harmful to patients. Similarly, although biologics exhibit site-specific action, they have a shorter half-life in the body and are expensive.
Biologics, such as monoclonal antibodies, have been reported to show immunogenicity. To overcome the limitations associated with conventional therapy, gene therapy has been introduced in the market. A phase I clinical trial was conducted in which a therapeutic gene encoding the IL-1 receptor antagonist was successfully transferred and expressed. This IL-1 receptor antagonist was able to reduce the disease in animal models. Such studies tend to encourage the use of gene therapy as an intervention for the treatment of RA. Hence, the abovementioned factors are expected to fuel the growth of the global anti-inflammatory drugs market during the forecast period.
Loss of patents is a major challenge impeding the anti-inflammatory drugs market growth. The global market is currently witnessing the loss of patents on major drugs. The loss of patent protection has led to the entry of generic drugs into the global market, which is available at lower prices than branded drugs. The entry of generic drug manufacturers into the market has propelled the major vendors to provide heavy rebates on their existing products, which, in turn, decreases their market share. The monetary loss to these vendors is subjected to generic erosion.
In addition, the Patient Protection and Affordable Care Act, implemented under the Biologics Price Competition and Innovation Act in the US, promote the approval of biosimilars in the US and allows generic drug manufacturers to refer data from already approved biological drugs. Such government proposals enacted under the law are likely to increase the competition in the market. For instance, HUMIRA accounted for approximately 61% of AbbVie's total revenue in 2021. The drug has already lost its patent rights in the US. Therefore, AbbVie competitors, such as Amgen, have applied to the EMA and the US FDA to grant marketing approval for HUMIRA biosimilar.
To remain competitive and prevent generic erosion, AbbVie must launch new product launches and initiate new indications or brand extensions for its existing products, such as HUMIRA. The new product must generate sufficient revenue that can cover the cost spent on research and development and replace the revenues of profitable products that are likely to be launched by the competitors. Hence, such factors are expected to hinder the growth of the global anti-inflammatory drugs market during the forecast period.
The market report includes the adoption lifecycle of the anti-inflammatory drugs market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Anti-inflammatory Therapeutics Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the autoimmune drugs market.
GlaxoSmithKline Plc - The company operates under multiple segments including pharmaceuticals, and vaccines among others with a high focus on pharmaceuticals.?
The anti-inflammatory therapeutics market report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth by the RA segment will be significant during the forecast period. RA is an autoimmune and inflammatory disease characterized by joint pain. The disease arises when the body's immune system is triggered against the healthy cells in the body by mistake and, hence, called autoimmune. This causes inflammation in the affected part of the body.
Get a glance at the market contribution of various segments View PDF Sample
The RA segment shows a gradual increase in the market share of USD 45.16 billion in 2017 and continued to grow until 2021. Arthritis is a leading cause of disability, which causes aching, pain, stiffness, and swelling of the joints. The most common types are osteoarthritis, rheumatoid arthritis, lupus, gout, and fibromyalgia. By 2040, an estimated 78 million (26%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis. Arthritis can be a hurdle to physical activity due to miserable joint pain, and inactivity associated with arthritis can lead to conditions such as cardiovascular disease, diabetes, and obesity. Hence, such a high prevalence and incidence rate of arthritis (of which rheumatoid arthritis is one of the most common types) will increase the demand for anti-inflammatory drugs, thus driving market growth. The RA segment of the global market is expected to grow at a moderate pace during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
North America is estimated to contribute 45% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the anti-inflammatory drugs market during the forecast period.
The market in North America dominated the global market in 2022. The growth of the market in this region is primarily driven by the sales of approved drugs for the treatment of conditions causing inflammation and the increasing prevalence of several associated risk factors for the condition. The market is growing due to the high prevalence of Immunomodulatory drugs and autoimmune diseases, which, in turn, increases the demand for such therapeutics. Furthermore, the CDC estimated that by 2040, about 78.00 million US adults are projected to have doctor-diagnosed arthritis. Hence, such a high prevalence of arthritis increases the risk of inflamed conditions, which is expected to drive the growth of the market in North America during the forecast period.
Although the US has many approved corticosteroids for the treatment of the condition and advanced diagnostic infrastructure, the high cost of these drugs is a potential challenge to the market. To mitigate this challenge, various vendors are offering patient assistance programs. Furthermore, vendors such as AbbVie are striving to develop newer biologics that are based on novel mechanisms of action. Such initiatives by the vendors are likely to drive market growth in this region. However, the patent loss is a major hurdle that is expected to hinder the market growth during the forecast period.
The outbreak of COVID-19 in 2020 severely impacted the market in North America. However, the lifting of lockdowns, followed by the rescheduling of patient visits to clinics and the adoption of contactless delivery of such therapeutics, was increased in 2021 and 2022; and it is expected to boost the growth of the regional market during the forecast period.
Technavio categorizes the global anti-inflammatory therapeutics market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent global pharmaceuticals market covers products and companies engaged in research and development or production of generic drugs, non-generic drugs, and veterinary drugs. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.
The anti-inflammatory therapeutics market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Anti-inflammatory Therapeutics Market Scope |
|
Report Coverage |
Details |
Page number |
167 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.7% |
Market growth 2023-2027 |
USD 39.32 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
5.64 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 45% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Alvogen Iceland ehf, Amgen Inc., Amneal Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., Cipla Ltd., Eli Lilly and Co., F. Hoffmann-La Roche Ltd, Ferring BV, GlaxoSmithKline Plc, Johnson and Johnson, Lupin Ltd., Mylan N.V, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Sanofi SA |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Get access to Report Sample PDF !
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.